Inmune Bio, Inc. SEC filings INMB

Inmune Bio, Inc. has 601 filings in SEC EDGAR's recent list, going back to Jul 13, 2017. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (material agreement, unregistered share sale, regulation fd disclosure). The company's fiscal year ends on December 31.

Inmune Bio, Inc. SEC filings
Form Description Filed Period
10-Q Quarterly report Nov 5, 2026 Sep 30, 2026
8-K Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
Oct 29, 2026 Oct 27, 2026
424B5 Prospectus supplement Oct 29, 2026 —
8-K Current report
Regulation FD disclosure, Other events
Oct 21, 2026 Oct 21, 2026
4 Insider transaction Sep 23, 2026 Sep 15, 2026
3 Initial insider ownership Sep 23, 2026 Sep 8, 2026
4 Insider transaction Sep 17, 2026 Sep 15, 2026
3 Initial insider ownership Sep 16, 2026 Sep 8, 2026
8-K Current report
Officer or director change, Other events
Sep 14, 2026 Sep 8, 2026
10-Q Quarterly report Aug 6, 2026 Jun 30, 2026
8-K Current report
Other events
Jul 31, 2026 Jul 31, 2026
4 Insider transaction Jul 7, 2026 Jul 2, 2026
4 Insider transaction Jul 7, 2026 Jul 2, 2026
4 Insider transaction Jul 7, 2026 Jul 2, 2026
8-K Current report
Material agreement
Jul 1, 2026 Jun 30, 2026
8-K Current report
Other events
Jun 23, 2026 Jun 23, 2026
8-K Current report
Officer or director change, Shareholder vote results
Jun 17, 2026 Jun 16, 2026
8-K Current report
Other events
Jun 2, 2026 Jun 2, 2026
8-K Current report
Other events
May 14, 2026 May 14, 2026
10-Q Quarterly report May 7, 2026 Mar 31, 2026
8-K Current report
Material agreement, Regulation FD disclosure
May 5, 2026 Apr 29, 2026
DEF 14A Proxy statement Apr 23, 2026 Jun 16, 2026
10-K Annual report Mar 30, 2026 Dec 31, 2025
8-K Current report
Regulation FD disclosure
Feb 27, 2026 Feb 27, 2026
8-K Current report
Other events
Feb 23, 2026 Feb 23, 2026
8-K Current report
Other events
Feb 19, 2026 Feb 19, 2026
8-K Current report
Regulation FD disclosure
Feb 13, 2026 Feb 10, 2026
8-K Current report
Regulation FD disclosure
Jan 27, 2026 Jan 27, 2026
8-K Current report
Material agreement
Dec 23, 2025 Dec 22, 2025
8-K Current report
Material agreement
Dec 19, 2025 Dec 19, 2025
424B5 Prospectus supplement Dec 19, 2025 —
8-K Current report
Agreement ended
Dec 10, 2025 Dec 5, 2025
8-A12B/A Amendment no. 5 to form 8-a12b Dec 8, 2025 —
8-K Current report
Material agreement, Change to shareholder rights
Dec 8, 2025 Dec 5, 2025
8-K Current report
Other events
Dec 5, 2025 Dec 1, 2025
8-K Current report
Officer or director change
Dec 3, 2025 Dec 2, 2025
4 Insider transaction Dec 2, 2025 Dec 1, 2025
4 Insider transaction Dec 2, 2025 Dec 1, 2025
4 Insider transaction Dec 2, 2025 Dec 1, 2025
4 Insider transaction Dec 2, 2025 Dec 1, 2025
4 Insider transaction Dec 2, 2025 Dec 1, 2025
4 Insider transaction Dec 2, 2025 Dec 1, 2025
4 Insider transaction Dec 2, 2025 Dec 1, 2025
8-K Current report
Officer or director change
Nov 28, 2025 Nov 26, 2025
4 Insider transaction Nov 18, 2025 Nov 18, 2025
4 Insider transaction Nov 18, 2025 Nov 18, 2025
4 Insider transaction Nov 18, 2025 Nov 18, 2025
4 Insider transaction Nov 18, 2025 Nov 18, 2025
4 Insider transaction Nov 18, 2025 Nov 18, 2025
4 Insider transaction Nov 18, 2025 Nov 18, 2025
4 Insider transaction Nov 18, 2025 Nov 18, 2025
8-K Current report
Officer or director change, Shareholder vote results, Other events
Nov 18, 2025 Nov 18, 2025
8-K Current report
Regulation FD disclosure
Nov 10, 2025 Nov 10, 2025
8-K Current report
Results of operations
Oct 30, 2025 Oct 30, 2025
10-Q Quarterly report Oct 30, 2025 Sep 30, 2025
8-K Current report
Other events
Oct 28, 2025 Oct 23, 2025
DEF 14A Proxy statement Oct 14, 2025 Nov 18, 2025
8-K Current report
Other events
Oct 14, 2025 Oct 14, 2025
PRE 14A Preliminary proxy statement Oct 3, 2025 Oct 3, 2025
8-K Current report
Other events
Sep 30, 2025 Sep 29, 2025
3 Initial insider ownership Aug 18, 2025 Aug 4, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 14, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 14, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 14, 2025 —
8-K Current report
Results of operations, Other events
Aug 7, 2025 Aug 4, 2025
10-Q Quarterly report Aug 7, 2025 Jun 30, 2025
8-K Current report
Other events
Jul 29, 2025 Jul 29, 2025
8-K Current report
Other events
Jul 25, 2025 Jul 24, 2025
SCHEDULE 13G Ownership over 5% (passive) Jul 2, 2025 —
8-K Current report
Material agreement, Other events
Jun 30, 2025 Jun 27, 2025
424B5 Prospectus supplement Jun 30, 2025 —
8-K Current report
Other events
Jun 30, 2025 Jun 30, 2025
8-K Current report
Other events
Jun 26, 2025 Jun 26, 2025
S-8 Employee stock plan registration Jun 16, 2025 —
S-8 Employee stock plan registration Jun 16, 2025 —
8-K Current report
Officer or director change, Shareholder vote results, Other events
Jun 10, 2025 Jun 10, 2025
8-K Current report
Other events
May 14, 2025 May 14, 2025
DEFR14A Revised definitive proxy statement May 9, 2025 —
8-K Current report
Results of operations
May 8, 2025 May 8, 2025
10-Q Quarterly report May 8, 2025 Mar 31, 2025
8-K Current report
Auditor change
May 7, 2025 May 7, 2025
8-K Current report
Other events
May 5, 2025 May 5, 2025
DEFA14A Additional proxy material Apr 25, 2025 —
DEF 14A Proxy statement Apr 21, 2025 May 28, 2025
8-K Current report
Regulation FD disclosure
Apr 16, 2025 Apr 16, 2025
8-K Current report
Other events
Apr 14, 2025 Apr 14, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Apr 10, 2025 —
8-K Current report
Regulation FD disclosure
Apr 9, 2025 Apr 3, 2025
8-K Current report
Other events
Apr 1, 2025 Apr 1, 2025
8-K Current report
Results of operations
Mar 27, 2025 Mar 27, 2025
10-K Annual report Mar 27, 2025 Dec 31, 2024
8-K Current report
Other events
Mar 24, 2025 Mar 24, 2025
424B5 Prospectus supplement Mar 7, 2025 —
8-K Current report
Regulation FD disclosure
Mar 4, 2025 Mar 4, 2025
8-K Current report
Other events
Feb 12, 2025 Feb 12, 2025
8-K Current report
Material agreement, Agreement ended, Other events
Feb 10, 2025 Feb 6, 2025
8-K Current report
Regulation FD disclosure
Feb 10, 2025 Feb 10, 2025
8-K Current report
Other events
Jan 28, 2025 Jan 28, 2025
SCHEDULE 13G Ownership over 5% (passive) Jan 15, 2025 —
8-A12B/A Amendment no. 4 to form 8-a12b Dec 9, 2024 —
8-K Current report
Material agreement, Change to shareholder rights, Officer or director change
Dec 9, 2024 Dec 4, 2024
4 Insider transaction Dec 9, 2024 Dec 5, 2024
4 Insider transaction Dec 9, 2024 Dec 5, 2024
4 Insider transaction Dec 9, 2024 Dec 5, 2024
4 Insider transaction Dec 9, 2024 Dec 5, 2024
4 Insider transaction Dec 9, 2024 Dec 5, 2024
4 Insider transaction Dec 9, 2024 Dec 5, 2024
4 Insider transaction Dec 9, 2024 Dec 5, 2024
8-K Current report
Other events
Nov 14, 2024 Nov 13, 2024
8-K Current report
Regulation FD disclosure
Nov 13, 2024 Nov 13, 2024
8-K Current report
Results of operations
Nov 1, 2024 Oct 31, 2024
10-Q Quarterly report Oct 31, 2024 Sep 30, 2024
8-K Current report
Other events
Oct 28, 2024 Oct 28, 2024
8-K Current report
Other events
Oct 25, 2024 Oct 24, 2024
SC 13G Ownership over 5% (passive) Oct 25, 2024 —
8-K Current report
Other events
Oct 24, 2024 Oct 24, 2024
8-K Current report
Other events
Oct 11, 2024 Oct 11, 2024
SC 13G/A Amended ownership over 5% (passive) Oct 2, 2024 —
4 Insider transaction Sep 30, 2024 Sep 30, 2024
8-K Current report
Other events
Sep 26, 2024 Sep 26, 2024
8-K Current report
Other events
Sep 17, 2024 Sep 17, 2024
4 Insider transaction Sep 16, 2024 Sep 12, 2024
4 Insider transaction Sep 16, 2024 Sep 12, 2024
8-K Current report
Material agreement, Other events
Sep 16, 2024 Sep 12, 2024
424B5 Prospectus supplement Sep 16, 2024 —
8-K Current report
Other events
Sep 3, 2024 Sep 3, 2024
8-K Current report
Material agreement
Aug 9, 2024 Aug 9, 2024
424B5 Prospectus supplement Aug 9, 2024 —
EFFECT Filing Aug 7, 2024 —
CORRESP Letter to the SEC Aug 5, 2024 —
S-3/A Amendment no. 1 to form s-3 Aug 2, 2024 —
8-K Current report
Results of operations
Aug 2, 2024 Aug 1, 2024
10-Q Quarterly report Aug 1, 2024 Jun 30, 2024
CORRESP Letter to the SEC Aug 1, 2024 —
8-K Current report
Other events
Jul 30, 2024 Jul 25, 2024
CORRESP Letter to the SEC Jul 30, 2024 —
8-K Current report
Shareholder vote results
Jul 19, 2024 Jul 19, 2024
8-K Current report
Officer or director change
Jul 5, 2024 Jul 5, 2024
8-K Current report
Other events
Jul 1, 2024 Jun 27, 2024
4 Insider transaction Jun 26, 2024 Jun 25, 2024
8-K Current report
Officer or director change
Jun 13, 2024 Jun 10, 2024
4 Insider transaction Jun 12, 2024 Jun 10, 2024
8-K Current report
Other events
May 30, 2024 May 30, 2024
DEF 14A Proxy statement May 29, 2024 Jul 19, 2024
8-K Current report
Bylaw or fiscal year change
May 23, 2024 May 22, 2024
4 Insider transaction May 16, 2024 May 14, 2024
4 Insider transaction May 16, 2024 May 14, 2024
4 Insider transaction May 16, 2024 May 14, 2024
4 Insider transaction May 16, 2024 May 14, 2024
4 Insider transaction May 16, 2024 May 14, 2024
4 Insider transaction May 16, 2024 May 14, 2024
4 Insider transaction May 16, 2024 May 14, 2024
4 Insider transaction May 16, 2024 May 14, 2024
8-K Current report
Officer or director change
May 16, 2024 May 14, 2024
8-K Current report
Results of operations, Other events
May 13, 2024 May 7, 2024
10-Q Quarterly report May 9, 2024 Mar 31, 2024
UPLOAD Letter from the SEC May 3, 2024 —
S-3 Shelf registration May 1, 2024 —
8-K Current report
Other events
Apr 30, 2024 Apr 29, 2024
8-K Current report
Material agreement, Other events
Apr 26, 2024 Apr 24, 2024
424B5 Prospectus supplement Apr 26, 2024 —
8-K Current report
Other events
Apr 25, 2024 Apr 23, 2024
4/A Filing Apr 24, 2024 Apr 19, 2024
4/A Filing Apr 24, 2024 Apr 19, 2024
4/A Filing Apr 24, 2024 Apr 19, 2024
4/A Filing Apr 24, 2024 Apr 19, 2024
4 Insider transaction Apr 23, 2024 Apr 19, 2024
4 Insider transaction Apr 23, 2024 Apr 19, 2024
4 Insider transaction Apr 23, 2024 Apr 19, 2024
4 Insider transaction Apr 23, 2024 Apr 19, 2024
8-K Current report
Material agreement, Other events
Apr 22, 2024 Apr 19, 2024
424B5 Prospectus supplement Apr 22, 2024 —
10-K/A Amended annual report Apr 16, 2024 Dec 31, 2023
8-K Current report
Other events
Apr 9, 2024 Apr 8, 2024
8-K Current report
Results of operations, Other events
Mar 29, 2024 Mar 28, 2024
10-K Annual report Mar 28, 2024 Dec 31, 2023
8-K Current report
Other events
Mar 27, 2024 Mar 26, 2024
8-K Current report
Regulation FD disclosure
Jan 30, 2024 Jan 30, 2024
8-K Current report
Other events
Jan 2, 2024 Jan 2, 2024
8-K Current report
Other events
Dec 18, 2023 Dec 18, 2023
8-A12B/A Amendment no. 3 to form 8-a12b Dec 18, 2023 —
8-K Current report
Material agreement, Change to shareholder rights
Dec 18, 2023 Dec 14, 2023
8-K Current report
Other events
Nov 29, 2023 Nov 29, 2023
8-K Current report
Other events
Nov 27, 2023 Nov 27, 2023
8-K Current report
Other events
Nov 15, 2023 Nov 15, 2023
4 Insider transaction Nov 13, 2023 Nov 10, 2023
8-K Current report
Results of operations
Nov 1, 2023 Nov 1, 2023
10-Q Quarterly report Nov 1, 2023 Sep 30, 2023
8-K Current report
Regulation FD disclosure, Other events
Oct 31, 2023 Oct 30, 2023
8-K Current report
Other events
Oct 18, 2023 Oct 16, 2023
8-K Current report
Other events
Sep 7, 2023 Sep 7, 2023
8-K Current report
Other events
Sep 5, 2023 Sep 5, 2023
8-K Current report
Material agreement
Aug 16, 2023 Aug 16, 2023
424B5 Prospectus supplement Aug 16, 2023 —
8-K Current report
Results of operations
Aug 8, 2023 Aug 7, 2023
10-Q Quarterly report Aug 7, 2023 Jun 30, 2023
8-K Current report
Other events
Aug 2, 2023 Aug 1, 2023
8-K Current report
Other events
Aug 1, 2023 Jul 31, 2023
8-K Current report
Other events
Jul 27, 2023 Jul 26, 2023
4 Insider transaction Jul 14, 2023 Jul 12, 2023

Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
INMB (Nasdaq)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
Boca Raton, FL
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1711754

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.